Natural ligands of PPARγ:: Are prostaglandin J2 derivatives really playing the part?

被引:108
作者
Nosjean, O [1 ]
Boutin, JA [1 ]
机构
[1] Inst Rech Servier, F-78290 Croissy Sur Seine, France
关键词
PPAR; prostaglandin J(2); thiazolidinedione; low-density lipoprotein; ligand;
D O I
10.1016/S0898-6568(01)00281-9
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The peroxisome proliferator-activated receptor (PPAR) family was discovered from an orphan nuclear receptor approach. and thereafter. three subtypes were identified, namely PPARalpha, PPARbeta or PPARdelta and PPARgamma. The two former seem to regulate lipid homeostasis, whereas the latter is involved, among others, in glucose homeostasis and adipocyte differentiation. PPARs were pharmacologically characterised first using peroxisome proliferators such as clofibrates, which demonstrate moderate affinity (efficiency at micromolar concentrations) and low PPARalpha/delta versus PPARgamma specificity. Hence, several laboratories have started the search for potent and subtype-specific natural PPAR activators. In this respect, prostaglandin (PG)-related compounds were identified as good PPARgamma agonists with varying specificity, the most notable PPARgamma ligand being 15-deoxy-Delta(12-14)-PGJ(2) (15d-PGJ(2)). Recently, an oxidized phosphatidylcholine was identified as a potent alternative (patho)physiological natural ligand of PPARgamma. In the present review, we discuss the different PPARgamma-dependent and -independent biological effects of the PG PPARgamma ligands and the concern about their low potency in molecular models as compared with thiazolidinediones (TZDs). a family of potent (nanomolar) synthetic PPARgamma ligands. Finally, the oxidized lipids are presented as a novel and interesting alternative for discovering potent PPARgamma activators in order to understand more in details the implications of PPARgamma in various pathophysiological conditions. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:573 / 583
页数:11
相关论文
共 139 条
[1]   Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation [J].
Adams, M ;
Montague, CT ;
Prins, JB ;
Holder, JC ;
Smith, SA ;
Sanders, L ;
Digby, JE ;
Sewter, CP ;
Lazar, MA ;
Chatterjee, VKK ;
O'Rahilly, S .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (12) :3149-3153
[2]   FORMATION OF THIOL CONJUGATES OF 9-DEOXY-DELTA-9,DELTA-12(E)-PROSTAGLANDIN-D2 AND DELTA-12(E)-PROSTAGLANDIN-D2 [J].
ATSMON, J ;
SWEETMAN, BJ ;
BAERTSCHI, SW ;
HARRIS, TM ;
ROBERTS, LJ .
BIOCHEMISTRY, 1990, 29 (15) :3760-3765
[3]   15-Deoxy-Δ12,14-prostaglandin J2 inhibits IL-10 and IL-12 production by macrophages [J].
Azuma, Y ;
Shinohara, R ;
Wang, PL ;
Ohura, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 283 (02) :344-346
[4]   Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells [J].
Bamba, H ;
Ota, S ;
Kato, A ;
Kawamoto, C ;
Fujiwara, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 273 (02) :485-491
[5]   Role of the peroxisome proliferator-activated receptor-γ (PPAR-γ) and its natural ligand 15-deoxy-Δ12,14-prostaglandin J2 in the regulation of microglial functions [J].
Bernardo, A ;
Levi, G ;
Minghetti, L .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2000, 12 (07) :2215-2223
[6]   Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ12,14-prostaglandin J2 [J].
Bishop-Bailey, D ;
Hla, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (24) :17042-17048
[7]   15-deoxy-Δ12,14-PGJ2, but not troglitazone, modulates IL-1β effects in human chondrocytes by inhibiting NF-κB and AP-1 activation pathways [J].
Boyault, S ;
Simonin, MA ;
Bianchi, A ;
Compe, E ;
Liagre, B ;
Mainard, D ;
Bécuwe, P ;
Dauça, M ;
Netter, P ;
Terlain, B ;
Bordji, K .
FEBS LETTERS, 2001, 501 (01) :24-30
[8]   Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells [J].
Brockman, JA ;
Gupta, RA ;
DuBois, RN .
GASTROENTEROLOGY, 1998, 115 (05) :1049-1055
[9]  
Butler R, 2000, CELL GROWTH DIFFER, V11, P49
[10]  
CASTRILLO A, 1992, MOL CELL BIOL, V12, P3094